CASSIOPEIA 试验中新诊断骨髓瘤患者维持前 FDG PET/CT 反应的预后价值
CASSIOPET 伴随研究评估维持前 PET/CT 反应(Deauville 评分)及骨髓多参数流式细胞术(MFC)微小残留病(MRD,10⁻⁵)对新诊断多发性骨髓瘤(NDMM)患者无进展生存(PFS)和总生存(OS)的预后价值。225 例可评估患者中,175 例基线 PET 阳性者维持前 92% 达 PET 阴性,单变量分析 PFS 更长(P = .019),OS 有延长趋势(P = .056);达雷妥尤单抗治疗组中 PET 阴性者 PFS 和 OS 延长(P = .0023 和 P = .033),双阴性(MFC 和 PET)经多变量分析独立关联 PFS(P = .0006)。
要点
- 维持前 92% 基线 PET 阳性患者达 PET 阴性,单变量分析 PFS 更长(P = .019),OS 有延长趋势(P = .056)。
- 达雷妥尤单抗组中维持前 PET 阴性者 PFS 和 OS 延长(P = .0023 和 P = .033)。
- 达雷妥尤单抗组中 MFC 和 PET 双阴性经多变量分析独立关联 PFS(P = .0006)。
核心结论
- 本研究证实维持前 PET 反应对接受达雷妥尤单抗联合治疗的新诊断多发性骨髓瘤患者具有预后相关性,并补充骨髓 MFC 的 MRD 检测。
研究设计与样本
- CASSIOPET 为 CASSIOPEIA 试验的伴随研究,评估维持前 PET/CT 反应(基于 Deauville 评分)及骨髓 MFC 检测 MRD(10⁻⁵)对 PFS 和 OS 的预后价值。
- 共 225 例患者有维持前 PET/CT 结果:112 例在 D-VTd 后接受达雷妥尤单抗治疗(其中 D-VTd 59 例、VTd 53 例),113 例在 D-VTd 或 VTd 后观察(其中 D-VTd 56 例、VTd 57 例)。
- CASSIOPEIA 试验注册号为 NCT02541383。
主要发现
- 175 例基线 PET 阳性患者中,维持前 92% 达 PET 阴性,单变量分析 PFS 更长(P = .019),OS 有延长趋势(P = .056)。
- 单变量分析中,PET 和 MFC 双阴性患者较至少 1 项阳性者 PFS 更好(P < .0001)。
- 达雷妥尤单抗治疗患者中,维持前 PET 阴性单变量分析关联 PFS 延长(P = .0023)和 OS 延长(P = .033)。
- 达雷妥尤单抗治疗患者中,MFC 和 PET 双阴性经多变量分析独立关联 PFS(P = .0006)。
关键数值与推荐
- 维持前 PET/CT 反应基于标准化 Deauville 评分评估。
- 骨髓 MRD 采用多参数流式细胞术(MFC)检测,灵敏度为 10⁻⁵。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The CASSIOPEIA trial demonstrated superior progression-free survival (PFS) with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (D-VTd) induction/consolidation, and with daratumumab maintenance vs observation in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The companion study, CASSIOPET, assessed the prognostic value of premaintenance (PM) positron emission tomography (PET)/computed tomography (CT) response, based on the standardized Deauville score on PFS and overall survival (OS), in addition to bone marrow (BM) minimal residual disease (MRD) detection by multiparameter flow cytometry (MFC) at 10-5 level. PM PET/CT was available for 225 patients: 112 patients treated with daratumumab after D-VTd (59) or bortezomib, thalidomide, and dexamethasone (VTd; 53), and 113 patients followed by observation after D-VTd (56) or VTd (57). At PM, 92% of the 175 baseline PET-positive patients achieved PET negativity, with a longer PFS in univariate analysis (P = .019) and a major trend of prolonged OS (P = .056). In univariate analysis, patients who achieved both PET and MFC negativity were found to have a better PFS (P < .0001) than those who had at least 1 positive result. In daratumumab-treated patients, PM PET negativity was associated with prolonged PFS and OS in univariate analysis (P = .0023 and P = .033, respectively), and double MFC and PET negativity was independently associated with PFS by multivariate analysis (P = .0006). This study confirms the prognostic relevance of a PM PET response in patients with NDMM treated with daratumumab in addition to MRD detection by MFC at the BM level. This trial was registered at ww.clinicaltrials.gov as #NCT02541383.
引用
- Kraeber-Bodéré F, Jamet B, Zweegman S, et al. Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial. Blood. 2025. PMID: 40991848. doi:10.1182/blood.2025030084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。